Clinical Trial Update: Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing the safety and efficacy of the Sandoz biosimilar HX575 epoetin alfa with US-licensed epoetin alfa in anemia due to chronic kidney dise…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Chronic Kidney Disease

Drugs mentioned

• HX575 epoetin alfa (epoetin alfa)
• US-licensed epoetin alfa (epoetin alfa)

Snippet

Sponsor: Sandoz | Conditions: Anemia, Chronic Kidney Disease (CKD) | Phase 3 | Status: COMPLETED | Results posted: 2017-05-12